De-Escalation of Therapy in Early-Stage TNBC

What is the Purpose of this Study?

This study focuses on patients who have been diagnosed with early-stage, triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with the immunotherapy drug pembrolizumab, followed by breast surgery. The purpose of the study is to determine whether observation is as effective as continuation of pembrolizumab postoperatively (after surgery) for treating TNBC breast cancer. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks (total of 1 year) after surgery. Researchers aim to compare the effectiveness of up to 27 weeks of post-surgical observation to up to 27 weeks of post-surgery pembrolizumab at reducing the risk of breast cancer returning or death in these patients, who achieved a pathologic complete response (no remaining invasive cancer found) after preoperative chemotherapy in combination with pembrolizumab. Pembrolizumab works by helping the immune system to fight cancer and is approved by the U.S. Food and Drug Administration. Participants will be randomly assigned to 1 of 2 groups. Group 1 will receive 27 weeks of pembrolizumab treatment after breast surgery; Group 2 will be observed by the study doctors and will not receive pembrolizumab.


Eligibility

  • * Age \>= 18 years
  • * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • * Triple Negative Breast Cancer:
Show more

Where can I participate?

  • Cedars-Sinai Cancer at Beverly Hills (THO) : Nikki Kem-Bernard
  • Cedars-Sinai Cancer at Hunt Cancer Center - TMPNCC (CSMC Affiliate)
  • Cedars-Sinai Cancer at SOCC : Nikki Kem-Bernard
  • Cedars-Sinai Cancer at Valley Oncology : Nikki Kem-Bernard
  • Huntington Hospital (CSMC Affiliate)


More about this Clinical Trial

What is the full name of this clinical trial?

A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Study Details
Disease Type/Condition

Breast cancer

Principal Investigator

Yuan, Yuan

Co-Investigators

Andrew Horodner, Benjamin King, David Chan, Dorothy Park, Hugo Hool, Jin Sun Bitar, Johnny Chang, Julie Huynh, Lauren DeStefano, Marc Botnick, Maryliza El-Masry, Monica Mita, Natasha Banerjee, Niki Patel Tank, Philomena McAndrew, Robert Reznik, Ryan Ponec, Swati Sikaria, Syed Jilani, Thomas Lowe, Tiffany Shaw, Tina Wang, Vanessa Dickey

Age Group

Adult

Phase

III

IRB Number

STUDY00002911

ClinicalTrials.gov ID

NCT05812807

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Name

Nikki Kem-Bernard

Email
Nikki.Bernard@cshs.org
Study Detail
Disease Type/Condition

Breast cancer

Principal Investigator

Yuan, Yuan

Age Group

Adult

Phase

III

IRB Number

A012103

ClinicalTrials.gov ID

NCT05812807

Key Eligibility
ClinicalTrials.gov

Contact
Name

Nikki Kem-Bernard

Email
Nikki.Bernard@cshs.org